AstraZeneca plc (AZN) PT Raised to GBX 5,250 at Kepler Capital Markets
AstraZeneca plc (LON:AZN) had its price target hoisted by investment analysts at Kepler Capital Markets from GBX 5,200 ($68.62) to GBX 5,250 ($69.28) in a research note issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Kepler Capital Markets’ target price points to a potential upside of 1.90% from the stock’s current price.
Other equities analysts have also recently issued reports about the stock. J P Morgan Chase & Co reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, July 13th. Credit Suisse Group decreased their target price on shares of AstraZeneca plc from GBX 5,000 ($65.98) to GBX 4,700 ($62.02) and set a “neutral” rating for the company in a research note on Friday, July 28th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($51.46) target price on shares of AstraZeneca plc and gave the company a “sell” rating in a research note on Wednesday, August 2nd. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, August 2nd. Finally, Citigroup Inc. reiterated a “buy” rating and issued a GBX 6,000 ($79.18) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 5,183.55 ($68.40).
TRADEMARK VIOLATION NOTICE: “AstraZeneca plc (AZN) PT Raised to GBX 5,250 at Kepler Capital Markets” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/astrazeneca-plc-azn-pt-raised-to-gbx-5250-at-kepler-capital-markets/1674915.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.